SONOMA PHARMACEUTICALS INC (SNOA) Stock Fundamental Analysis

NASDAQ:SNOA • US83558L3033

2.88 USD
+0.04 (+1.41%)
At close: Feb 25, 2026
2.76 USD
-0.12 (-4.17%)
After Hours: 2/18/2026, 8:02:28 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, SNOA scores 3 out of 10 in our fundamental rating. SNOA was compared to 192 industry peers in the Pharmaceuticals industry. The financial health of SNOA is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SNOA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • SNOA had negative earnings in the past year.
  • SNOA had a negative operating cash flow in the past year.
  • In the past 5 years SNOA always reported negative net income.
  • In the past 5 years SNOA always reported negative operating cash flow.
SNOA Yearly Net Income VS EBIT VS OCF VS FCFSNOA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

1.2 Ratios

  • SNOA's Return On Assets of -25.11% is in line compared to the rest of the industry. SNOA outperforms 58.33% of its industry peers.
  • SNOA's Return On Equity of -91.87% is in line compared to the rest of the industry. SNOA outperforms 40.63% of its industry peers.
Industry RankSector Rank
ROA -25.11%
ROE -91.87%
ROIC N/A
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
SNOA Yearly ROA, ROE, ROICSNOA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • With a decent Gross Margin value of 37.68%, SNOA is doing good in the industry, outperforming 61.46% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SNOA has declined.
  • The Profit Margin and Operating Margin are not available for SNOA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
SNOA Yearly Profit, Operating, Gross MarginsSNOA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SNOA has more shares outstanding
  • Compared to 5 years ago, SNOA has less shares outstanding
  • The debt/assets ratio for SNOA has been reduced compared to a year ago.
SNOA Yearly Shares OutstandingSNOA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
SNOA Yearly Total Debt VS Total AssetsSNOA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

2.2 Solvency

  • Based on the Altman-Z score of -18.69, we must say that SNOA is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -18.69, SNOA is doing worse than 80.21% of the companies in the same industry.
  • SNOA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • SNOA has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -18.69
ROIC/WACCN/A
WACC9.11%
SNOA Yearly LT Debt VS Equity VS FCFSNOA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 2.89 indicates that SNOA has no problem at all paying its short term obligations.
  • SNOA has a Current ratio (2.89) which is in line with its industry peers.
  • SNOA has a Quick Ratio of 2.05. This indicates that SNOA is financially healthy and has no problem in meeting its short term obligations.
  • SNOA has a Quick ratio of 2.05. This is comparable to the rest of the industry: SNOA outperforms 46.88% of its industry peers.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 2.05
SNOA Yearly Current Assets VS Current LiabilitesSNOA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • SNOA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.30%, which is quite impressive.
  • Looking at the last year, SNOA shows a very strong growth in Revenue. The Revenue has grown by 25.02%.
  • The Revenue has been decreasing by -4.44% on average over the past years.
EPS 1Y (TTM)55.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.76%
Revenue 1Y (TTM)25.02%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%56.58%

3.2 Future

  • The Earnings Per Share is expected to grow by 28.15% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, SNOA will show a very strong growth in Revenue. The Revenue will grow by 20.34% on average per year.
EPS Next Y-96.42%
EPS Next 2Y15.06%
EPS Next 3Y28.15%
EPS Next 5YN/A
Revenue Next Year11.38%
Revenue Next 2Y17.8%
Revenue Next 3Y20.34%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SNOA Yearly Revenue VS EstimatesSNOA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M
SNOA Yearly EPS VS EstimatesSNOA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2018 2019 2021 2024 2025 2026 2027 2028 0 -500 -1K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • SNOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SNOA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNOA Price Earnings VS Forward Price EarningsSNOA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNOA Per share dataSNOA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • SNOA's earnings are expected to grow with 28.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.06%
EPS Next 3Y28.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SNOA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SONOMA PHARMACEUTICALS INC

NASDAQ:SNOA (2/25/2026, 12:35:03 PM)

After market: 2.76 -0.12 (-4.17%)

2.88

+0.04 (+1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-03
Earnings (Next)06-15
Inst Owners3.49%
Inst Owner Change83.86%
Ins Owners1.24%
Ins Owner Change0%
Market Cap4.90M
Revenue(TTM)16.94M
Net Income(TTM)-3.48M
Analysts85.71
Price Target15.1 (424.31%)
Short Float %1.51%
Short Ratio1.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-23.22%
Min EPS beat(2)-45.24%
Max EPS beat(2)-1.2%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)13.07%
Min Revenue beat(2)-2.81%
Max Revenue beat(2)28.95%
Revenue beat(4)1
Avg Revenue beat(4)-1.23%
Min Revenue beat(4)-17.11%
Max Revenue beat(4)28.95%
Revenue beat(8)1
Avg Revenue beat(8)-8.23%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.29
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-2.2
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS9.96
BVpS2.23
TBVpS2.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.11%
ROE -91.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.68%
FCFM N/A
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
F-Score4
Asset Turnover1.22
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 121.32%
Cap/Sales 0.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 2.05
Altman-Z -18.69
F-Score4
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)91.77%
Cap/Depr(5y)85.45%
Cap/Sales(3y)0.91%
Cap/Sales(5y)0.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.76%
EPS Next Y-96.42%
EPS Next 2Y15.06%
EPS Next 3Y28.15%
EPS Next 5YN/A
Revenue 1Y (TTM)25.02%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%56.58%
Revenue Next Year11.38%
Revenue Next 2Y17.8%
Revenue Next 3Y20.34%
Revenue Next 5YN/A
EBIT growth 1Y26.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.58%
OCF growth 3YN/A
OCF growth 5YN/A

SONOMA PHARMACEUTICALS INC / SNOA FAQ

What is the ChartMill fundamental rating of SONOMA PHARMACEUTICALS INC (SNOA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SNOA.


Can you provide the valuation status for SONOMA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to SONOMA PHARMACEUTICALS INC (SNOA). This can be considered as Overvalued.


Can you provide the profitability details for SONOMA PHARMACEUTICALS INC?

SONOMA PHARMACEUTICALS INC (SNOA) has a profitability rating of 1 / 10.


What is the financial health of SONOMA PHARMACEUTICALS INC (SNOA) stock?

The financial health rating of SONOMA PHARMACEUTICALS INC (SNOA) is 4 / 10.


Can you provide the expected EPS growth for SNOA stock?

The Earnings per Share (EPS) of SONOMA PHARMACEUTICALS INC (SNOA) is expected to decline by -96.42% in the next year.